Paul D Chantler1,2,3, Carl D Shrader2,3,4, Lawrence E Tabone1,2,5, Alexandre C d'Audiffret1,3,6, Khumara Huseynova1,3,6, Steven D Brooks3,6, Kayla W Branyan1,3, Kristin A Grogg3, Jefferson C Frisbee2,3,7. 1. Division of Exercise Physiology, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA. 2. Clinical and Translational Sciences Institute, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA. 3. Center for Cardiovascular and Respiratory Sciences, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA. 4. Department of Family Medicine, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA. 5. Division of Bariatric Surgery, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA. 6. Division of Vascular Surgery, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA. 7. Department of Physiology and Pharmacology, West Virginia University Health Sciences Center, Morgantown, West Virginia, USA.
Abstract
OBJECTIVE: Chronic presentation of the MS is associated with an increased likelihood for stroke and poor stroke outcomes following occlusive cerebrovascular events. However, the physiological mechanisms contributing to compromised outcomes remain unclear, and the degree of cerebral cortical MVD may represent a central determinant of stroke outcomes. METHODS: This study used the OZR model of MS and clinically relevant, chronic interventions to determine the impact on cerebral cortical microvascular rarefaction via immunohistochemistry with a parallel determination of cerebrovascular function to identify putative mechanistic contributors. RESULTS: OZR exhibited a progressive rarefaction (to ~80% control MVD) of the cortical microvascular networks vs. lean Zucker rats. Chronic treatment with antihypertensive agents (captopril/hydralazine) had limited effectiveness in blunting rarefaction, although treatments improving glycemic control (metformin/rosiglitazone) were superior, maintaining ~94% control MVD. Chronic treatment with the antioxidant TEMPOL severely blunted rarefaction in OZR, although this ameliorative effect was prevented by concurrent NOS inhibition. CONCLUSIONS: Further analyses revealed that the maintenance of glycemic control and vascular NO bioavailability were stronger predictors of cerebral cortical MVD in OZR than was prevention of hypertension, and this may have implications for chronic treatment of CVD risk under stroke-prone conditions.
OBJECTIVE: Chronic presentation of the MS is associated with an increased likelihood for stroke and poor stroke outcomes following occlusive cerebrovascular events. However, the physiological mechanisms contributing to compromised outcomes remain unclear, and the degree of cerebral cortical MVD may represent a central determinant of stroke outcomes. METHODS: This study used the OZR model of MS and clinically relevant, chronic interventions to determine the impact on cerebral cortical microvascular rarefaction via immunohistochemistry with a parallel determination of cerebrovascular function to identify putative mechanistic contributors. RESULTS: OZR exhibited a progressive rarefaction (to ~80% control MVD) of the cortical microvascular networks vs. lean Zucker rats. Chronic treatment with antihypertensive agents (captopril/hydralazine) had limited effectiveness in blunting rarefaction, although treatments improving glycemic control (metformin/rosiglitazone) were superior, maintaining ~94% control MVD. Chronic treatment with the antioxidant TEMPOL severely blunted rarefaction in OZR, although this ameliorative effect was prevented by concurrent NOS inhibition. CONCLUSIONS: Further analyses revealed that the maintenance of glycemic control and vascular NO bioavailability were stronger predictors of cerebral cortical MVD in OZR than was prevention of hypertension, and this may have implications for chronic treatment of CVD risk under stroke-prone conditions.
Authors: M Vanhanen; K Koivisto; L Moilanen; E L Helkala; T Hänninen; H Soininen; K Kervinen; Y A Kesäniemi; M Laakso; J Kuusisto Journal: Neurology Date: 2006-09-12 Impact factor: 9.910
Authors: Sarah H Wild; Christopher D Byrne; Ioanna Tzoulaki; Amanda J Lee; Ann Rumley; Gordon D O Lowe; F Gerald R Fowkes Journal: Atherosclerosis Date: 2008-08-03 Impact factor: 5.162
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Steven D Brooks; Evan DeVallance; Alexandre C d'Audiffret; Stephanie J Frisbee; Lawrence E Tabone; Carl D Shrader; Jefferson C Frisbee; Paul D Chantler Journal: Am J Physiol Heart Circ Physiol Date: 2015-10-16 Impact factor: 4.733
Authors: Jefferson C Frisbee; Joshua T Butcher; Stephanie J Frisbee; I Mark Olfert; Paul D Chantler; Lawrence E Tabone; Alexandre C d'Audiffret; Carl D Shrader; Adam G Goodwill; Phoebe A Stapleton; Steven D Brooks; Robert W Brock; Julian H Lombard Journal: Am J Physiol Heart Circ Physiol Date: 2015-12-23 Impact factor: 4.733
Authors: Steven Brooks; Kayla W Branyan; Evan DeVallance; Roy Skinner; Kent Lemaster; J Whitney Sheets; Christopher R Pitzer; Shinichi Asano; Randall W Bryner; I Mark Olfert; Jefferson C Frisbee; Paul D Chantler Journal: Exp Physiol Date: 2018-03-25 Impact factor: 2.969
Authors: Brayden D Halvorson; John J McGuire; Krishna K Singh; Joshua T Butcher; Julian H Lombard; Paul D Chantler; Jefferson C Frisbee Journal: J Vasc Res Date: 2021-05-10 Impact factor: 1.934
Authors: Xingping Dai; Olga Bragina; Tongsheng Zhang; Yirong Yang; Gutti R Rao; Denis E Bragin; Gloria Statom; Edwin M Nemoto Journal: Crit Care Med Date: 2016-08 Impact factor: 7.598